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Abstract
To obtain a significant therapeutic effect transplanted genetically modified cells should have an
enhanced ability to survive and active expression of the therapeutic gene. In this paper, by
using  immunofluorescent  staining  we  investigated  the  functional  activity  of  the  gene-cell
formulation designed to deliver a therapeutic gene into the area of regeneration. As a model we
used transgenic SOD1-G93A mice with amyotrophic lateral sclerosis phenotype which received
xenotransplantation of human umbilical cord blood mononuclear cells, genetically modified with
adenoviral  expression  vector  encoding  vascular  endothelial  growth  factor  (VEGF)  and  the
reporter green fluorescent protein (EGFP). Results of the study allowed to establish not only the
duration of survival of transplanted cells, but also the efficiency of expression of recombinant
genes in genetically modified cells in vivo. Double immunofluorescent staining with antibodies
against human nuclear antigen HNA and VEGF detected HNA+/VEGF+ cells in the terminal stage
of  disease  15  weeks  after  transplantation.  These  data  suggest  that  genetically  modified
umbilical cord blood mononuclear cells, transplanted into SOD1-G93A transgenic mice, are able
to penetrate the blood-brain barrier and migrate into the area of degeneration of nerve tissue
and survive from the time of transplantation until the death of animals at the terminal stage of
disease. At that time adenoviral expression vector encoding therapeutic gene is functionally
active in transplanted cells, and secretory products of recombinant gene act on target cells by a
paracrine mechanism.
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